New diversity data from Phesi shows inclusion of Black and African American patients in clinical trials improving, but Asian, Hispanic and Latino groups significantly and consistently underrepresented
By analyzing protocol design data from Phase 2 and 3 clinical trials conducted in the United States only between year 2010 and 2020, Phesi showed that Asian, Hispanic and Latino, Native Americans and Alaska natives, Native Hawaiians and other Pacific Islander patient subpopulations were all significantly and consistently underrepresented over the decade.
Learning from the past: four pillars of clinical trial design
Although existing problems in clinical trial design have been intensified by COVID-19, the pandemic was not the root cause of these issues. Many trials are at risk due to design issues, resulting in costly protocol amendments and delays. At Phesi, we take a four pillars approach that lets sponsors tackle long-standing problems in trial design.